EXPRS2 — ExpreS2ion Biotech Holding AB Balance Sheet
0.000.00%
- SEK19.95m
- -SEK26.26m
- SEK12.21m
Annual balance sheet for ExpreS2ion Biotech Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 139 | 111 | 57.6 | 81.5 | 47.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 7.11 | 10.8 | 10.6 | 12.7 | 8.4 |
| Prepaid Expenses | |||||
| Total Current Assets | 146 | 132 | 68.7 | 95.4 | 57.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.21 | 0.91 | 1.77 | 1.53 | 0.465 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 152 | 137 | 78.7 | 105 | 65.1 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.46 | 31.4 | 11.4 | 38.2 | 28.3 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.6 | 34 | 13.3 | 40.1 | 29.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Other Equity | |||||
| Total Equity | 140 | 103 | 65.4 | 64.8 | 35.7 |
| Total Liabilities & Shareholders' Equity | 152 | 137 | 78.7 | 105 | 65.1 |
| Total Common Shares Outstanding |